JP2010503409A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010503409A5 JP2010503409A5 JP2009528468A JP2009528468A JP2010503409A5 JP 2010503409 A5 JP2010503409 A5 JP 2010503409A5 JP 2009528468 A JP2009528468 A JP 2009528468A JP 2009528468 A JP2009528468 A JP 2009528468A JP 2010503409 A5 JP2010503409 A5 JP 2010503409A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- composition according
- peptide
- azurin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84435806P | 2006-09-14 | 2006-09-14 | |
| PCT/US2007/078371 WO2008033987A2 (en) | 2006-09-14 | 2007-09-13 | Compositions and methods to prevent cancer with cupredoxins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013209725A Division JP2014050390A (ja) | 2006-09-14 | 2013-10-04 | クプレドキシンによって癌を予防する組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010503409A JP2010503409A (ja) | 2010-02-04 |
| JP2010503409A5 true JP2010503409A5 (enExample) | 2010-11-04 |
Family
ID=39184582
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009528468A Withdrawn JP2010503409A (ja) | 2006-09-14 | 2007-09-13 | クプレドキシンによって癌を予防する組成物および方法 |
| JP2013209725A Pending JP2014050390A (ja) | 2006-09-14 | 2013-10-04 | クプレドキシンによって癌を予防する組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013209725A Pending JP2014050390A (ja) | 2006-09-14 | 2013-10-04 | クプレドキシンによって癌を予防する組成物および方法 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2061498A4 (enExample) |
| JP (2) | JP2010503409A (enExample) |
| KR (1) | KR20090059152A (enExample) |
| CN (1) | CN101595124A (enExample) |
| AU (1) | AU2007296429A1 (enExample) |
| BR (1) | BRPI0714987A2 (enExample) |
| CA (1) | CA2663498A1 (enExample) |
| IL (1) | IL197602A0 (enExample) |
| MX (1) | MX2009002787A (enExample) |
| NO (1) | NO20091267L (enExample) |
| RU (1) | RU2009113812A (enExample) |
| SG (1) | SG174784A1 (enExample) |
| WO (1) | WO2008033987A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7556810B2 (en) | 2005-07-19 | 2009-07-07 | The Board Of Trustees Of The University Of Ilinois | Compositions and methods to control angiogenesis with cupredoxins |
| US9096663B2 (en) | 2001-02-15 | 2015-08-04 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof |
| US7381701B2 (en) | 2001-02-15 | 2008-06-03 | The Borad Of Trustees Of The University Of Illinois | Compositions and methods for treating conditions related to ephrin signaling with cupredoxins |
| US10675326B2 (en) | 2004-10-07 | 2020-06-09 | The Board Of Trustees Of The University Of Illinois | Compositions comprising cupredoxins for treating cancer |
| US9968685B2 (en) | 2004-10-07 | 2018-05-15 | Brad N. Taylor | Methods to treat cancer with cupredoxins |
| US9598470B2 (en) * | 2004-10-07 | 2017-03-21 | Craig W. Beattie | Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways |
| US9434770B2 (en) | 2004-10-07 | 2016-09-06 | Tapas K Das Gupta | Modified cupredoxin derived peptides |
| AP2007003959A0 (en) | 2004-10-07 | 2007-04-30 | Ananda Chakrabarty | Cupredoxin derived transport agents and methods ofuse thereof |
| AU2006269879A1 (en) | 2005-07-19 | 2007-01-25 | The Board Of Trustees Of The University Of Illinois | Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof |
| JP2010511408A (ja) | 2006-12-04 | 2010-04-15 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | 癌をＣｐＧリッチＤＮＡおよびキュプレドキシンで治療するための組成物および方法 |
| WO2008098216A2 (en) * | 2007-02-08 | 2008-08-14 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to prevent cancer with cupredoxins |
| US12331360B2 (en) | 2017-09-29 | 2025-06-17 | Oncgnostics Gmbh | Risk determination for neoplasia and cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7491394B2 (en) * | 2001-02-15 | 2009-02-17 | The Board Of Trustees Of The University Of Illinois | Cytotoxic factors for modulating cell death |
| CN1506375A (zh) * | 2002-12-12 | 2004-06-23 | 浙江养生堂天然药物研究所有限公司 | 具有广谱抗肿瘤作用的细菌蛋白天青蛋白及其用途和含有其的药物组合物 |
| AP2007003959A0 (en) * | 2004-10-07 | 2007-04-30 | Ananda Chakrabarty | Cupredoxin derived transport agents and methods ofuse thereof |
| KR20080040631A (ko) * | 2005-05-20 | 2008-05-08 | 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 | 에프린 신호전달과 관련된 질환을 쿠프레독신으로 치료하기위한 조성물과 방법 |
| JP2009502797A (ja) * | 2005-07-19 | 2009-01-29 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | 血管形成をキュプレドキシンで制御するための組成物および方法 |
-
2007
- 2007-09-13 BR BRPI0714987-5A patent/BRPI0714987A2/pt not_active Application Discontinuation
- 2007-09-13 RU RU2009113812/10A patent/RU2009113812A/ru unknown
- 2007-09-13 AU AU2007296429A patent/AU2007296429A1/en not_active Abandoned
- 2007-09-13 KR KR1020097007352A patent/KR20090059152A/ko not_active Withdrawn
- 2007-09-13 SG SG2011064334A patent/SG174784A1/en unknown
- 2007-09-13 JP JP2009528468A patent/JP2010503409A/ja not_active Withdrawn
- 2007-09-13 EP EP07842403A patent/EP2061498A4/en not_active Withdrawn
- 2007-09-13 WO PCT/US2007/078371 patent/WO2008033987A2/en not_active Ceased
- 2007-09-13 CN CNA2007800417624A patent/CN101595124A/zh active Pending
- 2007-09-13 CA CA002663498A patent/CA2663498A1/en not_active Abandoned
- 2007-09-13 MX MX2009002787A patent/MX2009002787A/es not_active Application Discontinuation
-
2009
- 2009-03-15 IL IL197602A patent/IL197602A0/en unknown
- 2009-03-26 NO NO20091267A patent/NO20091267L/no not_active Application Discontinuation
-
2013
- 2013-10-04 JP JP2013209725A patent/JP2014050390A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010503409A5 (enExample) | ||
| RU2009113812A (ru) | Композиции и способы для профилактики рака с помощью купредоксинов | |
| CA2437983C (en) | Transporters comprising spaced arginine moieties | |
| ES2989204T3 (es) | Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2) | |
| RU2009125599A (ru) | Композиции и способы лечения рака cpg-богатой днк и купредоксинами | |
| US20110206610A1 (en) | Compositions and methods for enhancing drug delivery across and into epithelial tissues | |
| KR102741242B1 (ko) | 국소 조성물 및 용도 | |
| NZ587105A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| AU2018389121A1 (en) | Botulinum toxin cell binding domain polypeptides and methods of use for treatments of fibrosis associated disorders | |
| JP2014050390A5 (enExample) | ||
| BRPI0810384B1 (pt) | terapia enzimática anticâncer | |
| CN102482323B (zh) | 新型肽及其应用 | |
| CA3148827A1 (en) | Compositions and methods of using c/ebp alpha sarna | |
| WO2004108088A3 (en) | Methods and compositions for interferon therapy | |
| EP3480212B1 (en) | Il13ralpha2 peptide and its uses | |
| JP2014531469A (ja) | Ｋｖ１．３カリウムチャネルの薬理学的標的化による肥満症および肥満症関連障害の治療 | |
| US20200188451A1 (en) | OXALOBACTER FORMIGENES (Of)-DERIVED FACTORS FOR THE TREATMENT OF TREATMENT/PREVENTION OF EXCESS OXALATE LEVELS | |
| CN106924260B (zh) | 化合物在制备用于治疗脑胶质瘤的药物中的用途 | |
| TWI496579B (zh) | 類鋅手指胜肽、其表現質體、及包含其之醫藥組成物之用途 | |
| US11820837B2 (en) | Modified peptides and associated methods of use | |
| US10793601B2 (en) | Therapeutic spalt-like transcription factor 4 (SALL4) peptide | |
| CN114364691B (zh) | 作为纤维化基质积累的抑制剂的肽 | |
| Şahin et al. | FAP-targeted CAR T-cell therapy: A promising approach for the treatment of Peyronie’s disease | |
| Yang et al. | Replacement of the Lys linker with an Arg linker resulting in improved melanoma uptake and reduced renal uptake of Tc-99m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptide | |
| Wada et al. | Translocation of an Aib-containing peptide through cell membranes |